Introducing EMJ Oncology 5.1

Introducing EMJ Oncology 5.1

Oncology October 24, 2017 at 9:14 AM 0 comments

United Kingdom, October 24, 2017: Welcome to this year’s issue of EMJ Oncology, which is filled with the latest developments from the world of cancer studies. Inside, you will find cutting-edge abstracts detailing ongoing research; the latest peer-reviewed articles focussed on the treatment of, detection of, and screening for cancers;Read More

Introducing EMJ Cardiology 5.1

Introducing EMJ Cardiology 5.1

Cardiology October 12, 2017 at 9:21 AM 0 comments

United Kingdom, October 12, 2017: European Medical Journal would like to welcome you to the latest edition of EMJ Cardiology. Packed with the latest research findings and opinions surrounding the human heart, this eJournal brings something truly unique. The 2017 European Society of Cardiology (ESC) annual congress, held in Barcelona,Read More

MC2 Therapeutics A/S Announces First Patient Dosed in Pivotal US Phase 3 Trial in Psoriasis Vulgaris

Dermatology October 12, 2017 at 9:19 AM 0 comments

First patient dosed in the pivotal Phase 3 trial assessing the safety and efficacy of MC2-01 Cream in US Topline results are expected in Q3 2018 Copenhagen, Denmark, 11 October, 2017 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that first patient has been dosedRead More

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Uncategorized October 10, 2017 at 4:32 PM 0 comments

BEKINDA®1 12 mg Phase II study successfully met its primary endpoint, improving primary efficacy outcome of stool consistency by an absolute difference of 19.4% vs. placebo and comparing favorably with previously reported outcomes from studies of Xifaxan® (rifaximin) and Viberzi® (eluxadoline)2 IBS is one of the most common gastrointestinal disorders,Read More

Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

Uncategorized October 10, 2017 at 4:03 PM 0 comments

Tuebingen, Germany and Houston, Texas, USA, 04 October, 2017 – The Series E funding was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and others. This latest financing was also strongly supported by new life science investors and Amgen, a world-leading biotechnology company and strategic partnerRead More

Regulatory Approval in Europe Granted for Synthon’s Glatiramer Acetate 40 mg/ml

Neurology October 10, 2017 at 3:42 PM 0 comments

Nijmegen, the Netherlands, 05 October, 2017 – Synthon today announced that it has successfully concluded the decentralized procedures for glatiramer acetate 40 mg/ml pre-filled syringe for the treatment of relapsing forms of multiple sclerosis and received regulatory approval in Europe. Synthon’s three-times-a-week glatiramer acetate is a therapeutically equivalent version ofRead More

CE Marking for World’s Only Integrated HIV Self-Test from Atomo Diagnostics Gives Access to Safe, Accurate and Reliable Self-Testing

Hematology, Reproductive Health October 10, 2017 at 10:21 AM 0 comments

Atomo HIV Self Test granted CE Mark; will facilitate rollout in European and other global markets Test will be available commercially during 2018 via retail, e-commerce and public health channels Simple, safe, accurate results from a single drop of blood in minutes 3rd generation test detects HIV antibodies earlier thanRead More

Shuwen Biotech Receives CE Mark for EGFR Mutation PCR Kit for Lung Cancer

Oncology, Respiratory September 19, 2017 at 10:13 AM 0 comments

Deqing, China, 18 September, 2017 – Shuwen Biotech announced today that it has received CE-IVD marking for its EGFR real time PCR detection kit allowing the company to market its kit in countries that recognize the designation. The CE Marked kit showcases Shuwen’s strengthening research and development capabilities which ultimatelyRead More

RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S.

Gastroenterology, Oncology September 19, 2017 at 10:11 AM 0 comments

Esomeprazole Strontium Delayed-Release (DR) Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI) indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions PPIs are one of the most commonly prescribed classes of medications in the U.S., with an estimated marketRead More

Robust Performance of OncoBEAM™ RAS CRC Liquid Biopsy Testing in Routine Clinical Practice for Colorectal Cancer Patients Highlighted at ESMO 2017

Hematology September 11, 2017 at 8:36 AM 0 comments

Hamburg, Germany, 08 September, 2017 – Sysmex Inostics, a subsidiary of Sysmex Corporation, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology is pleased to announce new data from a large real-world prospective evaluation of the OncoBEAM™ RAS CRC test for routine clinicalRead More